Delivery Order SPE2DB25D3022-SPE2DB25FWAZC

Award Date 3/26/25
Potential Completion Date 3/27/25
Potential Value $1.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the delivery of 4,564,728,550 units of 10 mg dextroamphetamine tablets, with a ceiling value of $4,143.30 and a completion date of May 29, 2024. The contract is a Delivery Order under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with the DLA, valued up to $999,999,999.00 through December 31, 2025. This...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,565,724,223 dextroamphetamine 20 mg tablets in packages of 30. The fixed-price delivery order, valued at $1,080.66, has a completion date of September 9, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999 through...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,026.75, is for the delivery of 4,567,426,586 units of 20 mg dextroamphetamine-amphetamine tablets. The contract is a Delivery Order with a Firm Fixed Price pricing type, and has an ultimate completion date of March 3, 2025. It is not designated as a set-aside contract. AmerisourceBergen holds a...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is for the delivery of 4,568,543,073 dextroamphetamine 5 mg tablets in lots of 100. The contract has a ceiling value of $1,937.12 and is a firm fixed price delivery order. The contract is not set aside and has an ultimate completion date of June 16, 2025. Amerisourcebergen Drug Corp holds a significant...
This federal contract award was issued by the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense, to Amerisourcebergen Drug Corp., a major pharmaceutical distributor. The contract, valued at $2,709.02, is for the delivery of 4,562,376,802 dextroamphetamine tablets, 10 mg, with an ultimate completion date of October 4, 2023. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc.,...
This is a firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4,568,500 units of 5 mg dextroamphetamine tablets. The $1,937.12 contract has a completion date of June 11, 2025 and is not set aside. AmerisourceBergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a comprehensive global pharmaceutical support...
This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, provides the Defense Logistics Agency (DLA) Troop Support Medical with a delivery order for 4,565,652,514 units of dextroamphetamine solution. The $1,612.71 firm-fixed-price contract has a completion date of September 2, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999 through December 2025, to deliver a...
This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $2,379.38 firm-fixed-price contract is for the delivery of 4,566,357,650 units of 5 mg dextroamphetamine-amphetamine tablets, which will be completed by November 7, 2024. The award is not designated with a set-aside requirement, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC)...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $1,143.66, is for the delivery of 4,567,018,305 units of dextroamphetamine 5mg tablets. The contract has a firm fixed price and an ultimate completion date of January 24, 2025. This award is a delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award is for the delivery of 4,568,506,769 tablets of dextroamphetamine-amphetamine 20 mg to the Defense Logistics Agency (DLA), a defense agency. The contract has a firm fixed price, with a ceiling value of $1,734.15, and a completion date of June 11, 2025. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is not set aside and is awarded as a delivery order. Amerisourcebergen Drug Corp...
  • SPE2DB25D3022
    Indefinite Delivery Contract
  • SPE2DB25D3022-SPE2DB25FWAZC
    Delivery Order

This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the delivery of 4,567,722,276 units of 10 mg dextroamphetamine tablets. The contract has a ceiling value of $1,238.20 and runs through March 27, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award does not have a set-aside designation, indicating open competition.

Generated 6/29/25, 12:52 AM